Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
26 juil. 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501 IRVINE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”)...
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
02 juil. 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
29 juin 2021 16h07 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
18 mai 2021 08h00 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results
13 mai 2021 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS) Strengthens senior leadership team with four key additions IRVINE, Calif., May ...
Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress
05 mai 2021 16h01 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021
04 mai 2021 16h01 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation
26 avr. 2021 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives
19 avr. 2021 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
30 mars 2021 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS) First patient to be enrolled in Phase 2 clinical trial of AT-1501 in islet cell transplantation for...